Semaglutide
FDA APPROVED · RXGLP-1 receptor agonist
Also known as: Ozempic, Wegovy, Rybelsus
FDA approved and prescription only. Sold as Ozempic (type 2 diabetes) and Wegovy (weight management).
Strong, human-grade evidence
- Regulatory standing. FDA-approved prescription medicine
- Human trials. Backed by controlled human studies
- Registered human trials. 748 registered studies on ClinicalTrials.gov, most advanced Phase 4
- 1 cited source. Cited references provided
A read on the weight of evidence and regulatory standing behind this compound. It is not a safety score, not a purity or quality rating, and not medical advice. It is not a claim that this compound treats, cures, or prevents any condition, and not an endorsement or a recommendation to buy or use it. A low score means the evidence is thin — not that a product is unsafe; a high score means the evidence is strong — not that anyone should take it. PLOBT is independent and takes no money from any vendor; no company can pay to change this score.
Proven in large human trials: about 15% average weight loss, strong blood-sugar control, and reduced cardiovascular events. This is one of the best-evidenced compounds in this library.
What it is
Mimics the GLP-1 hormone: it increases insulin secretion when blood sugar is high, slows stomach emptying, and reduces appetite.
What the research says
The STEP Phase 3 trials showed roughly 15% average body-weight reduction.
Approved on the SUSTAIN trial program.
The SELECT trial showed reduced major cardiovascular events in certain populations.
Published literature
Live from Europe PMC. Peer-reviewed papers discussing Semaglutide in their title or abstract, most-cited first. This is how much has been published — not how much is proven in humans. It counts landmark trials, animal studies and reviews alike.
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
Once-Weekly Semaglutide in Adults with Overweight or Obesity.
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.
EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD).
Registered human trials
Live from ClinicalTrials.gov, the US NIH registry of human studies, refreshed daily. Counts studies where Semaglutide is the intervention being tested.
A Study to Determine the Feasibility of Online Recruitment of People Using an Anti-Obesity Medication for Weight Loss
SUSTAIN SWITCH: A Research Study to Compare Two Dose Schedules of Semaglutide Taken Once Weekly in People With Type 2 Diabetes
Semaglutide and Tirzepatide for Genetic Aging Delay in Adults With Obesity
INcreTin-based thERapies for Cardiovascular Event PrevenTion in Patients With and Without ASCVD (INTERCEPT-ASCVD)
Phase and status counts reflect the 100 most recent studies; the registered total above is exact.
FDA recalls & enforcement
Live from openFDA. Times the FDA required a Semaglutide product to be pulled from the market, with the stated reason. A recall is a specific batch or manufacturing action, not a verdict on the compound itself.
CGMP Deviations: Intermittent exposure to temperature excursion during storage.
Recalled by Cardinal Health Inc.
What people log it for
Descriptive, based on what users track. Not an endorsement or a suggested use.
Risks & unknowns
- Common GI side effects: nausea, vomiting, constipation, especially while escalating the dose.
- Muscle loss can occur without adequate protein and resistance training.
- Illegal research and counterfeit versions are widespread and have prompted FDA and EMA warnings.
- It is a prescription medicine. Use outside medical supervision is unsafe and unlawful.
Doses reported in studies & protocols
Approved schedules escalate slowly (for example starting at 0.25 mg and stepping up over months under a prescriber). Follow a clinician, not a forum. This is not a recommendation.
Purity reality
A top counterfeit target. Only pharmacy-dispensed product has a verified supply chain.
None yet. PLOBT does not publish invented purity numbers. Real third-party COA data, mapped to vendor and batch, is in development — and it is the one thing we refuse to fake.
Sources
We cite peer-reviewed journals, PubMed/PMC, FDA and university sources, not vendor marketing.